A5086743431- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Immune Cell Function and Interaction
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Prostate Cancer Treatment and Research
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Escherichia coli research studies
- Vibrio bacteria research studies
- Liver physiology and pathology
- Blood transfusion and management
- Bacterial Genetics and Biotechnology
- Blood donation and transfusion practices
- Epigenetics and DNA Methylation
- Analytical Methods in Pharmaceuticals
- Intramuscular injections and effects
- Extracellular vesicles in disease
- Cholinesterase and Neurodegenerative Diseases
- Genetic Syndromes and Imprinting
- Medicinal Plants and Neuroprotection
Children's Hospital of Philadelphia
2002-2022
The University of Texas MD Anderson Cancer Center
2017-2018
Royal Prince Alfred Hospital
2015
Jewish General Hospital
2010-2011
McGill University
2010-2011
United States Department of the Army
2009
University of Leicester
2007-2008
Madigan Army Medical Center
2003
Hesco (United States)
2003
University of Pennsylvania
2002
Abstract The administration of ex vivo culture-expanded mesenchymal stromal cells (MSCs) has been shown to reverse symptomatic neuroinflammation observed in experimental autoimmune encephalomyelitis (EAE). mechanism by which this therapeutic effect occurs remains unknown. In an effort decipher MSC mode action, we found that conditioned medium inhibits EAE-derived CD4 T cell activation suppressing STAT3 phosphorylation via MSC-derived CCL2. Further analysis demonstrates the is dependent on...
Phenotypic characterization of immune cells in the bone marrow (BM) patients with acute myeloid leukemia (AML) is lacking.T-cell infiltration was quantified on BM biopsies from 13 AML, and flow cytometry performed aspirates (BMAs) 107 AML who received treatment at The University Texas MD Anderson Cancer Center. authors evaluated expression inhibitory receptors (programmed cell death protein 1 [PD1], cytotoxic T-lymphocyte antigen 4 [CTLA4], lymphocyte-activation gene 3 [LAG3], T-cell...
Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) correlate of poor response to atezolizumab (anti-PD-L1) in large clinical trials advanced kidney, breast, and bladder cancers. In pre-clinical models, combined blockade PD-L1 the IL-6 receptor (IL6R) causes synergistic regression tumors substantially improves anti-tumor CD8+ cytotoxic T lymphocyte...
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. The IMvigor130 trial reveals more favorable effects with atezolizumab combined gemcitabine and (GemCis) (GemCarbo). This study investigates the immunomodulatory as potential explanation for these observations. Our findings indicate that improved outcomes GemCis GemCarbo are primarily observed patients pretreatment tumors exhibiting features restrained adaptive...
Abstract Background: Current treatments for mCRPC include the androgen receptor antagonist enzalutamide (enza). Enza may enhance IFNγ signaling and sensitize tumor cells to immune-mediated cell killing, making it a candidate combinations with PD-L1/PD-1 inhibitors. Responses have been observed in patients (pts) receiving inhibitor or without enza. Therefore, atezolizumab (atezo), humanized anti-PD-L1 monoclonal antibody that inhibits interaction between PD-L1 its receptors, is being examined...
Abstract Alagille syndrome (AGS) is an autosomal dominant disorder characterized by bile duct paucity along with cardiovascular, skeletal, and ophthalmologic defects. The identification of JAG1 as the AGS disease gene revealed crucial role Notch signaling pathway in development multiple organ systems humans. Patients identical mutations demonstrate extreme clinical variability, suggesting that other factors may influence severity developmental defects this disorder. We have defined temporal...
Atezolizumab has shown antitumor activity in patients with ovarian cancer. Dual blockade of programmed death-ligand 1 (PD-L1) and VEGF enhances anticancer immunity augments several cancers. The safety efficacy atezolizumab plus bevacizumab were evaluated cancer.In this open-label, multicenter phase Ib study, platinum-resistant cancer received intravenous (1,200 mg) (15 mg/kg) once every 3 weeks. primary endpoint was safety; secondary endpoints included overall response rate (ORR), duration...
Abstract Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are IHC. We analyzed paired IHC data on UC samples using the SP142 and 22C3 assays from phase 3 IMvigor130 trial found discordant findings summarized four phenotypes: positive both (PD-L1 double positive; PD-L1DP), assay only (SP142 single SP142SP), (22C3 22C3SP),...
<p>Figure S4</p>
<p>FigS1</p>
<div>Abstract<p>Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are IHC. We analyzed paired data on samples using the SP142 and 22C3 assays from phase III IMvigor130 trial found discordant findings summarized four phenotypes: positive both assays, assay only, negative double negative. only cancers were associated with more favorable ICB...
<p>FigS3</p>
<p>TableS1</p>
<p>Fig S2</p>
Using a tissue-specific microarray screen in combination with chromosome anomalies the mouse, we identified novel imprinted gene, Inpp5f_v2 on mouse 7. Characterization of this gene reveals 3.2-kb transcript that is paternally expressed brain. variant related 4.7-kb transcript, Inpp5f, an inositol phosphatase biallelically mouse. uses alternative transcriptional start site within intron Inpp5f and thus has unique first exon. Whereas other transcripts have exon located 1 longer (such as at...
The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced metastatic urothelial carcinoma (mUC). Additional treatment were evaluated will be reported separately.Patients had mUC that progressed during following with a platinum-containing regimen....
Abstract The molecular mechanisms of pulmonary vascular development are poorly understood. Cell‐specific developmental pathways influenced by cell–cell signaling. Notch signaling molecules highly conserved receptors active in many cell‐fate determination systems. Recent observations and a ligand, Jagged1, suggest their importance morphogenesis, particularly development. We performed systematic evaluation Notch1/Jagged1 gene protein expression the developing mouse lung from embryonic day 11...